Altiratinib
- DCC-2701
- Soluble in DMSO
- MF: C26H21F3N4O4
- MW: 510.46
Description
Altiratinib was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases. This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations. Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo. Through its balanced inhibitory potency versus MET, TIE2, and VEGFR2, Altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis. Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.
More Information
| Parent CAS No. | 1345847-93-9 |
|---|---|
| Chemical Name | N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1C=C(NC(=O)C2(CC2)C(=O)NC2C=C(F)C(OC3C=CN=C(NC(=O)C4CC4)C=3)=CC=2F)C=CC=1F |
| MFCD | N.A. |
| InChi | InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34) |
| InChiKey | GNNDEPIMDAZHRQ-UHFFFAOYSA-N |
| CID | 54576299 |
| Short Description | MET, TIE2 (TEK), and VEGFR2 (KDR) kinases inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1581 | SU 11274 |
From $99.00 |
| 1582 | Foretinib |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1838 | ARQ 197 |
From $99.00 |
| 1850 | BMS 540215 |
From $121.00 |
| 1864 | Brivanib alaninate |
From $99.00 |
| 1891 | SU 6668 |
From $110.00 |
| 1914 | SGX 523 |
From $132.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.